SOURCE: BioCube, Inc.

May 25, 2011 16:05 ET

BioCube, Inc. and Battelle Memorial Institute Extend Agreement Granting BioCube the Rights to Battelle's Environmentally Safe Microaerosol Decontamination Technology

NEW YORK, NY--(Marketwire - May 25, 2011) - BioCube, Inc. (OTCQB: BICB) (PINKSHEETS: BICB), a "Life Sciences" company that specializes in advancing the use of electro-chemical activation (ECA) technology in today's commercial markets, announced today that it has extended its agreement with Battelle Memorial Institute (Battelle), the operator of U.S. Department of Energy's Pacific Northwest National Laboratory (PNNL).

The initial agreement signed on January 20, 2010 provided BioCube with nonexclusive domestic rights and exclusive rights in Canada, China, Mexico and Europe to develop and market the microaerosol-based technology developed by Battelle at PNNL and products that result therefrom as well as access to Battelle's test data compiled over the last 4 years that demonstrates the efficacy of licensed technology. The executed Amendment #1 summarizes specific patent filings in regions of interest to BioCube, as well as incorporates intellectual property rights to the "Vortex Aerosol Generator" (VAG) developed by the project research partner, Institute of Highly Pure Elements in St. Petersburg, Russia.

As previously announced by BioCube, Inc., it intends to further collaborate with PNNL and its Russian research partners to complete the development of VAG that will be used in an environmentally safe decontamination system modeled after research conducted at PNNL. The system developed at PNNL has demonstrated effective handling of microbial and fungal cells, spores, and viruses that are the core of such infections as MRSA infection, Avian Flu, Swine Flu and common molds.

There are a variety of methods allowing for decontamination of pathogens. However, the majority of these methods have serious limitations because they are either toxic, or have significant negative effects on sensitive equipment and interior materials. BioCube's system will be environmentally safe, with a minimal effect on humans and animals, using solutions that are biodegradable, non-toxic and economically efficient.

BioCube believes that this decontamination technology holds significant promise as a long-term solution to a growing problem of dealing with pathogen compromised facilities and will initially focus on applications in the healthcare and transportation markets.

In addition to microaerosol applications, BioCube is exploring other numerous uses for its aqueous solutions, which has conclusively demonstrated its superior properties in wound care and sterilization applications.

About Battelle Memorial Institute (Battelle)

Battelle is the world's largest independent research and development organization with 22,000 employees in more than 130 locations worldwide. Headquartered in Columbus, Ohio, Battelle manages or co-manages six national laboratories for the U.S. Department of Energy, including Pacific Northwest National Laboratory (PNNL) in Richland, Wash. PNNL employs 4,900 staff, has an annual budget of nearly $1.1 billion, and has been managed by Battelle since the lab's inception in 1965.

About BioCube, Inc.

BioCube, Inc. is a "Life Sciences" company that specializes in advancing the use of electro-chemical activation (ECA) technology in today's commercial markets. BioCube seeks to improve the safety and well being of its customers by providing a sanitary workspace, and believes its product achieves this goal by resolving the pressing need for a viable solution that can categorically sterilize hard to clean microbial environments, and do it in the most environmentally conscious way possible. BioCube is concerned with the environmental future of our planet. For that reason, the Company is focused on developing products that do not rely on harsh chemicals to be effective in its applications and by doing so have positive impact on the environment and help preserve existing natural resources. In a competitive global marketplace, BioCube plans to offer a highly effective, simple to use system, with a seemingly never-ending number of commercial applications. These solutions can be used in a variety of applications, from destroying microorganisms, to neutralizing chemical agents, to cleaning and degreasing surfaces or even purifying water, and can be applied in liquid, aerosol or frozen forms.

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Investors are cautioned that these forward-looking statements involve uncertainties and risks that could cause actual performance and results of operations to differ materially from those anticipated. These risks and uncertainties include issues related to the ability to: obtain sufficient funding to continue operations, maintain adequate cash flow, profitably exploit new ventures, as well as other factors set forth in BioCube, Inc. most recently filed Form 10-K and Form 10-Q reports. The forward-looking statements contained herein represent the Company's judgment as of the date of this release and it cautions readers not to place undue reliance on such statements. BioCube, Inc. assumes no obligation to update the statements contained in this release.

Contact Information